BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients

Viruses, Journal Year: 2023, Volume and Issue: 15(8), P. 1659 - 1659

Published: July 30, 2023

SARS-CoV-2 vaccination is the standard of care for prevention COVID-19 disease. Although triggers both humoral and cellular immune response, efficacy currently evaluated by measuring antibodies only, whereas adaptative immunity unexplored. Our aim to test cell-mediated response after three doses BNT162b vaccine in two cohorts fragile patients: Common Variable Immunodeficiency (CVID) patients Kidney Transplant Recipients (KTR) compared healthy donors. We enrolled 10 controls (HCs), 19 CVID 17 KTR patients. HC third dose had successfully mounted response. A positive correlation between Anti-Spike Trimeric IgG concentration neutralizing antibody titer was also observed. groups showed a lower HCs. IFN-γ release induced epitopes Spike protein stimulated CD4+ CD8+ T cells similar among vaccinated HC, KTR. Patients infected more efficient only In conclusion, an but not vaccine, suggesting that evaluation cell responses could be sensitive marker immunization these subjects.

Language: Английский

Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis

Journal of the Neurological Sciences, Journal Year: 2023, Volume and Issue: 456, P. 122852 - 122852

Published: Dec. 20, 2023

Language: Английский

Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders

Vaccine, Journal Year: 2024, Volume and Issue: 42(23), P. 126061 - 126061

Published: June 16, 2024

Language: Английский